1. Pharmacogenomics J. 2020 Apr;20(2):235-245. doi: 10.1038/s41397-019-0103-3.
Epub  2019 Oct 18.

Influence of CYP2B6 activity score on the pharmacokinetics and safety of single 
dose efavirenz in healthy volunteers.

Zubiaur P(1), Saiz-Rodríguez M(1), Ochoa D(1)(2), Belmonte C(1)(2), Román 
M(1)(2), Mejía G(1)(2), Martín-Vilchez S(1), Abad-Santos F(3)(4)(5)(6).

Author information:
(1)Clinical Pharmacology Department, Instituto Teófilo Hernando, Universidad 
Autónoma de Madrid (UAM) Instituto de Investigación Sanitaria La Princesa (IP), 
Hospital Universitario de La Princesa, Madrid, Spain.
(2)UICEC Hospital Universitario de La Princesa, Plataforma SCReN (Spanish 
Clinical Research Network), Instituto de Investigación Sanitaria La Princesa 
(IP), Madrid, Spain.
(3)Clinical Pharmacology Department, Instituto Teófilo Hernando, Universidad 
Autónoma de Madrid (UAM) Instituto de Investigación Sanitaria La Princesa (IP), 
Hospital Universitario de La Princesa, Madrid, Spain. 
francisco.abad@salud.madrid.org.
(4)UICEC Hospital Universitario de La Princesa, Plataforma SCReN (Spanish 
Clinical Research Network), Instituto de Investigación Sanitaria La Princesa 
(IP), Madrid, Spain. francisco.abad@salud.madrid.org.
(5)Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y 
Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. 
francisco.abad@salud.madrid.org.
(6)Pharmacology Department, Facultad de Medicina, Universidad Autónoma de 
Madrid, Madrid, Spain. francisco.abad@salud.madrid.org.

Efavirenz is a non-nucleoside reverse transcriptase inhibitor used as first-line 
therapy for the treatment of HIV infection. Cytochrome P450 (CYP) CYP2B6 G516T 
(rs3745274) is a well-known predictor of efavirenz disposition. Dose adjustment 
based on G516T variant has been shown to be beneficial. However, this variant 
cannot explain the entire variability of efavirenz pharmacokinetics. In this 
study, we evaluated the influence of 11 single-nucleotide polymorphisms (SNPs) 
in CYP2B6, CYP2A6, CYP3A and ABCB1 (ATP-binding cassette sub-family B member 1) 
on the pharmacokinetics and safety of efavirenz after single oral dose 
administration to 47 healthy volunteers. We designed and validated a CYP2B6 
activity score model based on two CYP2B6 SNPs (G516T and rs4803419) that 
predicted efavirenz disposition better than G516T alone.

DOI: 10.1038/s41397-019-0103-3
PMID: 31628422 [Indexed for MEDLINE]